NCT01869491View on ClinicalTrials.gov

Compound Sodium Alginate Double Action Chewable Tablet Symptomatic Relief Study

PHASE3CompletedINTERVENTIONAL
Enrollment

1,107

Participants

Timeline

Start Date

June 5, 2013

Primary Completion Date

May 31, 2014

Study Completion Date

May 31, 2014

Conditions
Gastroesophageal Reflux DiseaseDyspepsia
Interventions
DRUG

Compound Sodium Alginate Double Action Chewable Tablets

2 tablets four times daily

DRUG

Matching placebo tablets

2 tablets four times daily

Trial Locations (2)

Unknown

RB Investigational Sites, Beijing

RB Investigational Sites, Shanghai

All Listed Sponsors
lead

Reckitt Benckiser Healthcare (UK) Limited

INDUSTRY

NCT01869491 - Compound Sodium Alginate Double Action Chewable Tablet Symptomatic Relief Study | Biotech Hunter | Biotech Hunter